Showing 751-760 of 1100 results for "".
- Burt's Bees Natural Retinol Alternative Works Well in Sensitive Skinhttps://practicaldermatology.com/news/burts-bees-natural-retinol-alternative-works-well-in-sensitive-skin/2460430/Three new studies from Burt’s Bees highlight the safety and efficacy of Bakuchiol, a natural retinol alternative, as well as a new facial oil and lip balm. The findings were presented online at the American Academy of Dermatology (AAD
- Johnson & Johnson Consumer Health Research Sheds Light on the Development of the Skin Microbiomehttps://practicaldermatology.com/news/johnson-johnson-consumer-health-research-sheds-light-on-the-development-of-the-skin-microbiome/2460428/New Johnson & Johnson Consumer Health research provides key insights into how the infant microbiome develops from birth to childhood. The findings, based on 10 years of data, were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.
- ProTransit to Target Photodamage in Trials of New Nanoparticle Technologyhttps://practicaldermatology.com/news/protransit-to-target-photodamage-in-trials-of-new-nanoparticle-technology/2460418/ProTransit Nanotherapy plans to launch human clinical trials this summer with products that could target precursors of skin cancers. The company has developed therapies based nanoparticle technology invented at the University of Nebraska Medical Center to help prevent and potentially improve suns
- FDA Approves Dupixent for Children Aged 6 to 11 Years with Moderate-to-Severe ADhttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-aged-6-to-11-years-with-moderate-to-severe-ad/2460404/The US Food and Drug Administration (FDA) gave its nod to Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Dupixent comes in two doses, prescribed based on weight (300 mg every four weeks for children ≥15 to <30 kg and 200 mg eve
- Industry Responds to COVID-19: Dial Donates Products to FEMA, Encourages Americans to Participate in #IWashMyHandsFor Social Campaignhttps://practicaldermatology.com/news/industry-responds-dial-donates-products-to-fema-encourages-americans-to-participate-in-iwashmyhandsfor-social-campaign/2460398/Dial will donate more than 600,000 units of liquid hand soap, bar soap and body wash products to FEMA, supporting their mission to help people during disasters. In March 2020 Henkel announced a comprehensive
- SciBase Receives FDA Approval for Nevisense 3.0https://practicaldermatology.com/news/scibase-receives-fda-approval-for-nevisense-30/2460388/The FDA has approved SciBase AB's Nevisense 3.0, the third generation of their Nevisense system for early melanoma detection. Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in
- Accure Laser Gets CE Mark for Acne Treatmenthttps://practicaldermatology.com/news/accure-laser-gets-ce-mark-for-acne-treatment/2460386/Accure Acne, Inc. now has a European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris. The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands. Fo
- Calling All Heroes: Cutera Seeks to Honor COVID-19 Championshttps://practicaldermatology.com/news/calling-all-heroes-cutera-seeks-to-honor-covid-19-champions/2460380/From physicians going back to the ER and conducting hospital rounds to supporting food depositories and shelters, to doctors donating personal protective equipment, ventilators, and office facilities as needed during the COVID-19 global pandemic, Cutera wants to shine a spotlight on its customers
- FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Oldhttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-jublia-to-treat-onychomycosis-in-patients-as-young-as-six-years-old/2460371/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics received FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range incl
- Navigating the Ins and Outs of Your Insurance Coverage During COVID-19https://practicaldermatology.com/news/navigating-the-ins-and-outs-of-your-insurance-coverage-during-covid-19-1/2460349/Jason O’Dell, a financial consultant and insurance specialist at OJM Group, spoke with New Jersey-based dermatologist Jeanine Downie, MD and Chicagoland facial plastic surgeon Steve Dayan, MD about what to expect from insurance coverage during the pandemic and how to beef up your policies i